Detecting and managing patients with type 2 diabetic kidney disease: Proteinuria and cardiovascular disease  by Mitch, William E. et al.
Kidney International, Vol. 66, Supplement 92 (2004), pp. S97–S98
Detecting and managing patients with type 2 diabetic kidney
disease: Proteinuria and cardiovascular disease
WILLIAM E. MITCH, SHAHNAZ SHAHINFAR, TANIA Z. DICKSON, DICK DE ZEEUW,
and ZHONGXIN ZHANG
University of Texas Medical Branch, Galveston, Texas; Merck Research Laboratories, Merck & Co., Inc., Whitehouse Station,
New Jersey; and Department of Clinical Pharmacology, Groningen University Medical Centre, Groningen, The Netherlands
Detecting and managing patients with type 2 diabetic kidney
disease: Proteinuria and cardiovascular disease.
Background. The increasing prevalence of type 2 diabetes
(T2DM) places more patients at risk for developing chronic
kidney disease (CKD) or cardiovascular (CV) events. Effective
therapy for CKD or CV disease (CVD) requires a method of
identifying affected patients and monitoring the effectiveness
of therapy.
Methods. We tested the predictive value of proteinuria for
identifying patients at risk for progressive CDK and CVD, and
monitoring treatment was determined using RENAAL study
results.
Results. Baseline proteinuria identified patients at risk for
progressive CKD and CVD. Suppression of proteinuria was as-
sociated with decreased likelihood of CKD or CVD.
Conclusion. Proteinuria identifies the risk of CKD and CVD,
and can be used to monitor the effectiveness of therapy.
Epidemiologic analyses have uncovered two factors af-
fecting CKD patient care: CKD prevalence is larger than
suspected, with >10 million United States adults having
significant kidney damage, and the risk of CVD and mor-
tality is sharply increased by CKD [1]. More than half the
United States patients receiving dialysis treatment have
T2DM, and the number of estimated diabetics worldwide
(>150 million) is expected to double within 25 years [2].
The association of CKD and CVD and T2DM raises
clinically relevant questions. Is there a reliable marker
of CKD and CVD, and can the response to therapy be
monitored by a simple measurement? Additionally, is
nephropathy linked to increased CVD risk? Results from
the RENAAL study yield insight into the identification
and monitoring of CKD and CVD in patients with T2DM
and nephropathy [2, 3].
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METHODS
The RENAAL study included 1513 patients with
T2DM and nephropathy from 28 countries, with a
mean follow-up of 3.4 years [4]. Methods and inclu-
sion/exclusion criteria are described elsewhere [4]. Pa-
tients were stratified according to baseline proteinuria
of <2 or >2g/g creatinine. Patients were randomized to
either losartan or placebo on a background of conven-
tional antihypertensive therapy to achieve a goal blood
pressure of <140/90 mm Hg.
The prespecified CKD end point was a composite of
the time to doubling of serum creatinine, end-stage renal
disease (ESRD), or death. There also was a secondary
prespecified cardiovascular morbidity and mortality end
point consisting of myocardial infarction, stroke, first
hospitalization for CHF or unstable angina, coronary
or peripheral artery revascularization, or CV death. All
end points were adjudicated by an independent, blinded
committee.
Proteinuria was utilized as a marker of CKD progres-
sion, CVD risk, and treatment response. Multivariate
COX proportional hazards models were used to evalu-
ate the relationship between CKD and CVD. Baseline
covariates used in the model were CVD history, CHF his-
tory, age, gender, smoking, race, weight, seated diastolic
and systolic blood pressures (SiDBP, SiSBP), MAP, pulse
pressure, total cholesterol, estimated GFR, hemoglobin,
HBA1c, albuminuria, and treatment allocation. Changes
in proteinuria at six months were utilized to predict CVD
risk and treatment responses.
RESULTS
Baseline characteristics for the treatment groups were
similar [2, 3]. Proteinuria was a strong predictor of CKD
and CVD, and the relationship was almost linear. Pro-
teinuria >3 g/g increased the risk for the CKD com-
posite end point 5.2-fold, and ESRD alone by 8.1-fold
compared with proteinuria<1.5 g/g. Additionally, the risk
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for the CVD composite was 1.92-fold higher, and the CHF
risk was 2.7-fold higher in those with greater proteinuria.
Change in proteinuria at six months strongly predicted
CKD and CVD risk; a 30% increase in proteinuria was
associated with a risk increase for the CKD composite
(54%), ESRD (141%), CVD composite (7%), and CHF
(17%). A reduction in proteinuria during the same time
period was associated with a risk reduction for the CKD
composite (43%), ESRD (52%), CVD composite (32%),
and CHF (44%).
DISCUSSION
Angiotensin-receptor blockers delay progressive CKD
in patients with T2DM and nephropathy [4, 5]. RENAAL
results indicate that monitoring proteinuria identifies pa-
tients at risk and their response to treatment. Further-
more, the beneficial effects of losartan on CKD or CVD,
although affecting the kidney and heart, are not due solely
to lowering blood pressure.
Limitations of the analyses include the post hoc assign-
ment of proteinuria cutoffs [2, 3], and associations cannot
prove a cause-effect relationship about proposed mecha-
nisms. Other methods that suppress proteinuria (e.g., low
protein diets) might help evaluate whether these drugs
protect the kidney via greater suppression of protein-
uria, but again, responses to dietary changes could benefit
CKD and CVD damage in other ways [6].
CONCLUSION
Proteinuria is an effective identifier of patient risk for
CKD or CVD. As such, monitoring proteinuria is war-
ranted when treating type 2 diabetic patients.
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